Wild-type (senile) amyloidosis surgery
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sabawoon Mirwais, M.B.B.S, M.D.[2]
Overview
Surgery is not the mainstay of therapy for wild-type (senile) amyloidosis. Left ventricular assist devices (LVAD) implantation can be considered but a review of the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) database is necessary to better evaluate the outcomes of LVAD implantation in these patients. Despite the the deteriorating cardiac function of such patients, they are rarely considered for heart transplantation due to their advanced disease presentation, age, and associated comorbidities.
Surgery
- Surgery is not the mainstay of therapy for wild-type (senile) amyloidosis.
- Left ventricular assist devices (LVAD) implantation can be considered but a review of the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) database is necessary to better evaluate the outcomes of LVAD implantation in these patients.[1]
- Despite the the deteriorating cardiac function of such patients, they are rarely considered for heart transplantation due to their advanced disease presentation, age, and associated comorbidities.
References
- ↑ Paul L. Swiecicki, Brooks S. Edwards, Sudhir S. Kushwaha, Angela Dispenzieri, Soon J. Park & Morie A. Gertz (2013). “Left ventricular device implantation for advanced cardiac amyloidosis”. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. 32 (5): 563–568. doi:10.1016/j.healun.2013.01.987. PMID 23474361. Unknown parameter
|month=ignored (help)
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH